New research presented during the late-breaking trials program at the National Kidney Foundation Spring Clinical Meetings showed the anemia drug daprodustat has cardiovascular benefits comparable to erythropoiesis-stimulating agents.
Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor targeted to treat anemia of chronic kidney disease in both patients on dialysis and not on dialysis.
“Anemia is an important and frequent complication of chronic kidney disease, an increasing global health burden affecting 700 million patients worldwide with one in